Voyager Therapeutics
![Alexion Gains Voyager's Preclinical Capsid in $1B Pfizer Handoff](https://pharmtales.com/wp-content/uploads/2023/11/Alexion-Acquires-Voyagers-Preclinical-Capsid-for-Rare-Neurological-Disease-After-1B-Pfizer-Transfer.jpg)
Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer
Anika Sharma
Pfizer has transferred an AAV capsid designed for a rare neurological disease target to AstraZeneca’s rare disease subsidiary, Alexion, as ...